Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series

Three patients diagnosed with severe COVID‐19 pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneumonia became severe and survived. The thrid patient was diagnosed late and received...

Descripción completa

Detalles Bibliográficos
Autores principales: Surabotsophon, Manoon, Klai‐On, Yingyot, Thanachartwet, Vipa, Khunapornphairote, Sirote, Chamnanchanunt, Supat, Racharak, Theerapat, Laisuan, Wannada, Sahassananda, Duangjai, Hapunna, Samlee, Jinapuk, Somjit, Leelasetakul, Suthee, Desakorn, Varunee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675634/
https://www.ncbi.nlm.nih.gov/pubmed/33230415
http://dx.doi.org/10.1002/ccr3.3407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675634/
https://www.ncbi.nlm.nih.gov/pubmed/33230415
http://dx.doi.org/10.1002/ccr3.3407

Ejemplares similares